Abstract
Botulinium toxin (BT) has truly revolutionized the management of movements disorders, although the marketing authorization is limited to cervical dystonia and blepharo-spasm. Its mechanism of action as well as its efficacy and tolerance profile allow recurrent use. Its use has grown considerably in recent years following the demonstration of remarkable efficacy in other indications, that we will discuss in this communication.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
